

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

786-O

RRID:CVCL_1051

Type: Cell Line

Proper Citation

RRID:CVCL_1051

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1051

Proper Citation: RRID:CVCL_1051

Description: Cell line 786-O is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Renal cell carcinoma

Defining Citation: [PMID:721102](#), [PMID:1010528](#), [PMID:2041050](#), [PMID:6244232](#), [PMID:7915601](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:15585611](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22185343](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22949125](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:27993170](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30260228](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31267758](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 786-O

Synonyms: 786-o, 786O, 786-0, 786.O, 786-O RCC, RCC 786-O, RCC_7860, RCC 7860, 7860, 786-0WT

Cross References: BTO:BTO_0003781, CLO:CLO_0001486, EFO:EFO_0005707, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1932, BCRC:60243, BioGRID_ORCS_Cell_line:502, BioSample:SAMN03471906, BioSample:SAMN10988199, cancercellines:CVCL_1051, CCRID:1101HUM-PUMC000243, CCRID:3101HUMSCSP5059, CCRID:3101HUMTCHu186, CCRID:4201HUM-CCTCC00159, CCRID:5301HUM-KCB09014YJ, CCTCC:GDC0159, Cell_Model_Passport:SIDM00125, ChEMBL-Cells:ChEMBL3308018, ChEMBL-Targets:ChEMBL613102, CLS:300107, Cosmic:687936, Cosmic:875874, Cosmic:897461, Cosmic:905947, Cosmic:972929, Cosmic:974305, Cosmic:982276, Cosmic:1044259, Cosmic:1092589, Cosmic:1175848, Cosmic:1305372, Cosmic:1312360, Cosmic:1481416, Cosmic:1998431, Cosmic:2036676, Cosmic:2520637, Cosmic:2663796, Cosmic-CLP:905947, DepMap:ACH-000649, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS261AAA, ENCODE:ENCBS413VCR, ENCODE:ENCBS807WMR, GDSC:905947, GEO:GSM2128, GEO:GSM50226, GEO:GSM50290, GEO:GSM482711, GEO:GSM743488, GEO:GSM750838, GEO:GSM799371, GEO:GSM799377, GEO:GSM799434, GEO:GSM843437, GEO:GSM846283, GEO:GSM886845, GEO:GSM887909, GEO:GSM1153444, GEO:GSM1177874, GEO:GSM1177875, GEO:GSM1177876, GEO:GSM1181296, GEO:GSM1181322, GEO:GSM1669572, GEO:GSM2124635, IARC_TP53:18076, IARC_TP53:28222, IZSLER:BS TCL 124, KCB:KCB 200941YJ, LiGeA:CCLE_806, LINCS_LDP:LCL-1773, Lonza:1087, MetaboLights:MTBLS737, NCI-DTP:786-0, PharmacDB:7860_28_2019, PRIDE:PXD000335, PRIDE:PXD000589, PRIDE:PXD001493, PRIDE:PXD003105, PRIDE:PXD003539, PRIDE:PXD005453, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1051, PubChem_Cell_line:CVCL_1051, SKY/M-FISH/CGH:2782, Ubigen:YC-C113, Wikidata:Q54604950

ID: CVCL_1051

Record Creation Time: 20220427T215100+0000

Record Last Update: 20260904T021122+0000

Ratings and Alerts

No rating or validation information has been found for 786-O.

No alerts have been found for 786-O.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 1526 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Koh J, et al. (2026) ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. *Cancer research*, 86(7), 1676.

Chen Y, et al. (2026) USP15 stabilizes c-Myc to drive sunitinib resistance by suppressing cuproptosis in clear cell renal cell carcinoma. *Cell reports*, 45(5), 117328.

Shi H, et al. (2026) OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. *Cell death & disease*, 17(1).

Koochaki P, et al. (2026) Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism. *The EMBO journal*, 45(11), 3763.

Alhourani F, et al. (2026) Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer. *Cancer research*, 86(1), 236.

Zhang C, et al. (2026) Quantification of Single-Cell Cysteine Using an Electrochemical Nanosensor for Predicting Tumor Disulfidptosis Susceptibility. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(13), e23478.

Zhu X, et al. (2026) KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability. *iScience*, 29(4), 115198.

Wang J, et al. (2026) Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. *Cancer research*, 86(9), 2237.

Abou Alaiwi S, et al. (2026) Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability. *Cell reports*, 45(2), 116968.

Hatayama T, et al. (2026) Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma. *Urologic oncology*, 44(8), 108.

Wang C, et al. (2026) USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. *iScience*, 29(5), 115808.

Li Y, et al. (2026) Integrating Bulk and Single-Cell RNA-Seq Reveals Glycolysis-Associated Macrophages and Its Related Tumor Subgroup Signatures to Predict Prognosis and Therapy in Clear Cell Renal Cell Carcinoma. *Human mutation*, 2026, 3125551.

Liu X, et al. (2026) High throughput screening identifies sanguinarine chloride as a multi-faceted therapeutic agent for PRCC-TFE3 rRCC by targeting lactylation-driven VEGFB-VEGFR2 signaling and PMN-MDSC infiltration. *Journal of advanced research*.

Sobu R, et al. (2026) IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. *iScience*, 29(7), 116386.

Gu S, et al. (2026) MAGI3 deficiency unleashes β -catenin conformational change to drive metastatic progression and mTOR inhibitor resistance in ccRCC. *Cell death & disease*, 17(1).

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. *Cell death & disease*, 17(1).

Richmond G, et al. (2026) Large extracellular vesicles regulate endothelial angiogenic potential via paracrine and autocrine signaling. *The Journal of biological chemistry*, 302(3), 111193.

Heritz JA, et al. (2026) Targeting and dissociating HIF2 α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. *Communications medicine*, 6(1), 91.

Li YR, et al. (2026) Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma. *STAR protocols*, 7(1), 104340.

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. *Cell reports. Medicine*, 7(4), 102695.